Bone morphogenetic protein 9 (BMP9) controls lymphatic vessel maturation and valve formation

Blood

Volumn 122, Issue 4, 2013, Pages 598-607

  Levet, Sandrine ^a,b,c   Ciais, Delphine ^a,b,c   Merdzhanova, Galina ^a,b,c   Mallet, Christine ^a,b,c   Zimmers, Teresa A ^d   Lee, Se Jin ^e   Navarro, Fabrice P ^f   Texier, Isabelle ^f   Feige, Jean Jacques ^a,b,c   Bailly, Sabine ^a,b,c   Vittet, Daniel ^a,b,c  

^a INSERM   (France)

^b DIF   (France)

^c UNIV GRENOBLE ALPES   (France)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Laboratoire d'Electronique et Technologie de l'Information   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN 9; LYVE 1 PROTEIN; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; GDF2 PROTEIN, MOUSE; GLYCOPROTEIN; XLKD1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; LYMPH VESSEL; LYMPHANGIOGENESIS; LYMPHATIC DRAINAGE; MATURATION; MESENTERY; MOUSE; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; CELL CULTURE; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; NEWBORN; PHYSIOLOGY; PRENATAL DEVELOPMENT;

ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GLYCOPROTEINS; GROWTH DIFFERENTIATION FACTOR 2; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MESENTERY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 84886901002     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-472142     Document Type: Article

References (31)

1. Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell. 2010;140(4):460-476.
2. Rockson SG. Diagnosis and management of lymphatic vascular disease. J Am Coll Cardiol. 2008;52(10):799-806.
3. Norrmén C, Tammela T, Petrova TV, Alitalo K. Biological basis of therapeutic lymphangiogenesis. Circulation. 2011;123(12):1335-1351.
4. Petrova TV, Karpanen T, Norrmén C, et al. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med. 2004;10(9): 974-981.
5. Mäkinen T, Adams RH, Bailey J, et al. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev. 2005;19(3):397-410.
6. Norrmén C, Ivanov KI, Cheng J, et al. FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. J Cell Biol. 2009;185(3):439-457.
7. Sabine A, Agalarov Y, Maby-El Hajjami H, et al. Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation. Dev Cell. 2012; 22(2):430-445.
8. Bazigou E, Makinen T. Flow control in our vessels: vascular valves make sure there is no way back. Cell Mol Life Sci. 2012;70(6): 1055-1066.
9. Kanady JD, Dellinger MT, Munger SJ, Witte MH, Simon AM. Connexin37 and Connexin43 deficiencies in mice disrupt lymphatic valve development and result in lymphatic disorders including lymphedema and chylothorax. Dev Biol. 2011;354(2):253-266.
10. Bazigou E, Xie S, Chen C, et al. Integrin-alpha9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis. Dev Cell. 2009; 17(2):175-186.
11. Jurisic G, Maby-El Hajjami H, Karaman S, et al. An unexpected role of semaphorin3a-neuropilin-1 signaling in lymphatic vessel maturation and valve formation. Circ Res. 2012;111(4):426-436.
12. Bouvrée K, Brunet I, Del Toro R, et al. Semaphorin3A, Neuropilin-1, and PlexinA1 are required for lymphatic valve formation. Circ Res. 2012;111(4):437-445.
13. Roelen BA, van Rooijen MA, Mummery CL. Expression of ALK-1, a type 1 serine/threonine kinase receptor, coincides with sites of vasculogenesis and angiogenesis in early mouse development. Dev Dyn. 1997;209(4): 418-430.
14. David L, Mallet C, Keramidas M, et al. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res. 2008;102(8): 914-922.
15. Ricard N, Ciais D, Levet S, et al. BMP9 and BMP10 are critical for postnatal retinal vascular remodeling. Blood. 2012;119(25): 6162-6171.
16. Niessen K, Zhang G, Ridgway JB, Chen H, Yan M. ALK1 signaling regulates early postnatal lymphatic vessel development. Blood. 2010;115(8):1654-1661.
17. Bidart M, Ricard N, Levet S, et al. BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain. Cell Mol Life Sci. 2012;69(2): 313-324.
18. Tammela T, Saaristo A, Lohela M, et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood. 2005;105(12):4642-4648.
19. Gravier J, Navarro FP, Delmas T, et al. Lipidots: competitive organic alternative to quantum dots for in vivo fluorescence imaging. J Biomed Opt. 2011;16(9):096013.
20. Navarro FP, Berger M, Guillermet S, et al. Lipid nanoparticle vectorization of indocyanine green improves fluorescence imaging for tumor diagnosis and lymph node resection. J Biomed Nanotechnol. 2012;8(5):730-741.
21. Reddy ST, van der Vlies AJ, Simeoni E, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007;25(10):1159-1164.
22. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787-796.
23. Schulte-Merker S, Sabine A, Petrova TV. Lymphatic vascular morphogenesis in development, physiology, and disease. J Cell Biol. 2011;193(4):607-618.
24. Lutter S, Xie S, Tatin F, Makinen T. Smooth muscle-endothelial cell communication activates Reelin signaling and regulates lymphatic vessel formation. J Cell Biol. 2012;197(6): 837-849.
25. Kim JH, Peacock MR, George SC, Hughes CC. BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II. Angiogenesis. 2012;15(3):497-509.
26. Corti P, Young S, Chen CY, et al. Interaction between alk1 and blood flow in the development of arteriovenous malformations. Development. 2011;138(8):1573-1582.
27. David L, Feige JJ, Bailly S. Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev. 2009;20(3):203-212.
28. Cunha SI, Pietras K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood. 2011; 117(26):6999-7006.
29. Larrivée B, Prahst C, Gordon E, et al. ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway. Dev Cell. 2012;22(3): 489-500.
30. Sengle G, Ono RN, Sasaki T, Sakai LY. Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability. J Biol Chem. 2011; 286(7):5087-5099.
31. Zhou F, Chang Z, Zhang L, et al. Akt/Protein kinase B is required for lymphatic network formation, remodeling, and valve development. Am J Pathol. 2010;177(4): 2124-2133.